Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA yield high or low?
The EBITDA yield of 4.37% is 10% above its estimated 1-year average of 3.97%, near the high end of its estimated 1-year range (3.62%–4.55%).
As of 2026-10-06T20:58:54.644Z.
Calculation as of: 2026-10-06T20:58:54.644Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e34e8fdf56cc8068b10795b2cd23ca1cf428d99faa8853e43d8e56f6a2fe063d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
4.37%
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
6.35%
median of 216 covered companies
CURRENT VS SECTOR MEDIAN
-31.18%
vs the sector median at left
Market Cap
$419.87M
EBITDA Yield
N/A
TTM Avg
6.82%
3Y Avg
6.82%
5Y Avg
6.82%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | $422.72M | 4.37% | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 1.44% | 5.28% | 7.05% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | N/A | 6.82% | 6.82% | 6.82% |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | N/A | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2026-10-05 | 4.42% |
| 2026-10-02 | 4.51% |
| 2026-10-01 | 4.55% |
| 2026-09-30 | 4.39% |
| 2026-09-29 | 4.23% |
| 2026-09-28 | 4.18% |
| 2026-09-25 | 4.10% |
| 2026-09-24 | 4.14% |
| 2026-09-23 | 4.11% |
| 2026-09-22 | 4.03% |
| 2026-09-21 | 4.13% |
| 2026-09-18 | 4.20% |
| 2026-09-17 | 4.24% |
| 2026-09-16 | 4.25% |
| 2026-09-15 | 4.20% |
| 2026-09-14 | 4.09% |
| 2026-09-11 | 4.18% |
| 2026-09-10 | 4.09% |
| 2026-09-09 | 4.04% |
| 2026-09-08 | 3.98% |
| 2026-09-04 | 3.85% |
| 2026-09-03 | 3.83% |
| 2026-09-02 | 3.83% |
| 2026-09-01 | 3.85% |
| 2026-08-31 | 3.80% |
| 2026-08-28 | 3.79% |
| 2026-08-27 | 3.80% |
| 2026-08-26 | 3.76% |
| 2026-08-25 | 3.62% |
| 2026-08-24 | 3.71% |
| 2026-08-21 | 3.64% |
| 2026-08-20 | 3.74% |
| 2026-08-19 | 3.65% |
| 2026-08-18 | 3.87% |
| 2026-08-17 | 3.86% |
| 2026-08-14 | 3.74% |
| 2026-08-13 | 3.72% |
| 2026-08-12 | 3.74% |
| 2026-08-11 | 3.68% |
| 2026-08-10 | 3.90% |
| 2026-08-07 | 3.80% |
| 2026-08-06 | 3.89% |
| 2026-08-05 | 3.89% |
| 2026-08-04 | 3.76% |
| 2026-08-03 | 3.76% |
| 2026-07-31 | 3.82% |
| 2026-07-30 | 4.05% |
| 2026-07-29 | 4.20% |
